Clinical Trial Update: A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety and activity of SAR448501/DR-0201 in patients with autoimmune rheumatic diseases, including systemic lupus erythema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus

Drugs mentioned

• SAR448501/DR-0201

Snippet

Sponsor: Sanofi | Conditions: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) | Phase 1 | Status: RECRUITING